Publication

Radiotherapy as a Treatment Option for Local Disease Control in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.

Journal Paper/Review - Feb 14, 2022

Units
PubMed
Doi
Contact

Citation
Zehnder M, Amarov B, Abrunhosa-Branquinho A, Maiwald-Urosevic M, Mühleisen B, Saulite I, Anzengruber F, Imhof L, Navarini A, Cozzio A, Dummer R, Dimitriou F, Guenova E. Radiotherapy as a Treatment Option for Local Disease Control in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. Dermatology 2022; 238:967-976.
Type
Journal Paper/Review (English)
Journal
Dermatology 2022; 238
Publication Date
Feb 14, 2022
Issn Electronic
1421-9832
Pages
967-976
Brief description/objective

Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL, LT) is an aggressive lymphoma variant. Anthracycline-based chemotherapy with rituximab is recommended as first-line treatment. Radiotherapy (RT) has been considered as a therapeutic option for local disease control in patients with solitary or localized lesions.